Single cell gene expression profiling in Alzheimer’s disease

Stephen D Ginsberg; Shaoli Che; Scott E Counts; Elliott J Mufson

doi:10.1016/j.nurx.2006.05.007

. 2012 Sep 5;3(3):302–318. doi: 10.1016/j.nurx.2006.05.007

Single cell gene expression profiling in Alzheimer’s disease

Stephen D Ginsberg ^1,^2,^3,^✉, Shaoli Che ^1,², Scott E Counts ⁴, Elliott J Mufson ⁴

PMCID: PMC3593387 PMID: 16815214

Summary

Development and implementation of microarray techniques to quantify expression levels of dozens to hundreds to thousands of transcripts simultaneously within select tissue samples from normal control subjects and neurodegenerative diseased brains has enabled scientists to create molecular fingerprints of vulnerable neuronal populations in Alzheimer’s disease (AD) and related disorders. A goal is to sample gene expression from homogeneous cell types within a defined region without potential contamination by expression profiles of adjacent neuronal subpopulations and nonneuronal cells. The precise resolution afforded by single cell and population cell RNA analysis in combination with microarrays and real-time quantitative polymerase chain reaction (qPCR)—based analyses allows for relative gene expression level comparisons across cell types under different experimental conditions and disease progression. The ability to analyze single cells is an important distinction from global and regional assessments of mRNA expression and can be applied to optimally prepared tissues from animal models of neurodegeneration as well as postmortem human brain tissues. Gene expression analysis in postmortem AD brain regions including the hippocampal formation and neocortex reveals selectively vulnerable cell types share putative pathogenetic alterations in common classes of transcripts, for example, markers of glutamatergic neurotransmission, synaptic-related markers, protein phosphatases and kinases, and neurotrophins/neurotrophin receptors. Expression profiles of vulnerable regions and neurons may reveal important clues toward the understanding of the molecular pathogenesis of various neurological diseases and aid in identifying rational targets toward pharmacotherapeutic interventions for progressive, late-onset neurodegenerative disorders such as mild cognitive impairment (MCI) and AD.

Key Words: Microarray, neurodegeneration, RNA amplification, aging, qPCR, mild cognitive impairment, molecular fingerprint, postmortem human brain

References

1.Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA. 1989;262:2256–2551. [PubMed] [Google Scholar]
2.Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer’s disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001;15:169–173. doi: 10.1097/00002093-200110000-00002. [DOI] [PubMed] [Google Scholar]
3.Ginsberg SD, Schmidt ML, Crino PB, Eberwine JH, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer’s disease and related disorders. In: Peters A, Morrison JH, editors. Cerebral cortex: neurodegenerative and age-related changes in structure and function of cerebral cortex. New York: Kluwer Academic/Plenum; 1999. pp. 203–653. [Google Scholar]
4.Selkoe DJ. Alzheimer’s disease: genotypes, phenotypes, and treatments. Science. 1997;275:630–631. doi: 10.1126/science.275.5300.630. [DOI] [PubMed] [Google Scholar]
5.Trojanowski JQ, Lee VM. The Alzheimer’s brain: finding out what’s broken tells us how to fix it. Am J Pathol. 2005;167:1183–1188. doi: 10.1016/s0002-9440(10)61206-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. NGF family of neurotrophins and their receptors: early involvement in the progression of Alzheimer’s disease. In: Dawbarn D, Allen SJ, editors. Neurobiology of Alzheimer’s disease. 3rd ed. Oxford, UK: Oxford University Press; 2006. [Google Scholar]
7.Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer’s disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol. 1989;105:221–232. doi: 10.1016/0014-4886(89)90124-6. [DOI] [PubMed] [Google Scholar]
8.Mufson EJ, Bothwell M, Hersh LB, Kordower JH. Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: colocalization with cholinergic neurons. J Comp Neurol. 1989;285:196–217. doi: 10.1002/cne.902850204. [DOI] [PubMed] [Google Scholar]
9.Whitehouse PJ, Rice DL, Struble RG, Clark AW, Coyle JT, Delong MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237–1239. doi: 10.1126/science.7058341. [DOI] [PubMed] [Google Scholar]
10.Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2:1403–1403. doi: 10.1016/s0140-6736(76)91936-x. [DOI] [PubMed] [Google Scholar]
11.Hyman BT, van Hoesen GW, Damasio AR, Barnes CL. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168–1170. doi: 10.1126/science.6474172. [DOI] [PubMed] [Google Scholar]
12.Hyman BT, van Hoesen GW, Damasio AR. Memory-related neural systems in Alzheimer’s disease: an anatomic study. Neurology. 1990;40:1721–1730. doi: 10.1212/wnl.40.11.1721. [DOI] [PubMed] [Google Scholar]
13.Hof PR, Morrison JH. The aging brain: morphomolecular senescence of cortical circuits. Trends Neurosci. 2004;27:607–613. doi: 10.1016/j.tins.2004.07.013. [DOI] [PubMed] [Google Scholar]
14.Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer’s disease. J Neuropathol Exp Neurol. 1997;56:1095–1097. doi: 10.1097/00005072-199710000-00002. [DOI] [PubMed] [Google Scholar]
15.Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II. Standardization of the neuro-pathologic assessment of Alzheimer’s disease. Neurology. 1991;41:479–486. doi: 10.1212/wnl.41.4.479. [DOI] [PubMed] [Google Scholar]
16.Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol Aging. 1998;19:173–189. doi: 10.1016/s0197-4580(98)00052-9. [DOI] [PubMed] [Google Scholar]
17.Alzheimer A. Uber eine eigenartige Erkrangkung der Hirnrinde. All Z Psychiatr. 1907;64:146–148. [Google Scholar]
18.Skovronsky DM, Lee VM-Y, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis. 2006;1:151–170. doi: 10.1146/annurev.pathol.1.110304.100113. [DOI] [PubMed] [Google Scholar]
19.Cohen AS, Connors LH. The pathogenesis and biochemistry of amyloidosis. J Pathol. 1987;151:1–10. doi: 10.1002/path.1711510102. [DOI] [PubMed] [Google Scholar]
20.Iwai A, Yoshimoto M, Masliah E, Saitoh T. Non-Aβ component of Alzheimer’s disease amyloid (NAC) is amyloidogenic. Biochemistry. 1995;34:10139–10145. doi: 10.1021/bi00032a006. [DOI] [PubMed] [Google Scholar]
21.Masliah E, Iwai A, Mallory M, Ueda K, Saitoh T. Altered pre-synaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer’s disease. Am J Pathol. 1996;148:201–210. [PMC free article] [PubMed] [Google Scholar]
22.Schmidt ML, DiDario AG, Otvos L, Hoshi M, Kant JA, Lee VM-Y, et al. Plaque-associated neuronal proteins: a recurrent motif in neuritic amyloid deposits throughout diverse cortical areas of the Alzheimer’s disease brain. Exp Neurol. 1994;130:311–322. doi: 10.1006/exnr.1994.1209. [DOI] [PubMed] [Google Scholar]
23.Pasinetti GM. Inflammatory mechanisms in neurodegeneration and Alzheimer’s disease: the role of the complement system. Neurobiol Aging. 1996;17:707–716. doi: 10.1016/0197-4580(96)00113-3. [DOI] [PubMed] [Google Scholar]
24.Atwood CS, Martins RN, Smith MA, Perry G. Senile plaque composition and posttranslational modification of amyloid-β pep-tide and associated proteins. Peptides. 2002;23:1343–1350. doi: 10.1016/s0196-9781(02)00070-0. [DOI] [PubMed] [Google Scholar]
25.Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–890. doi: 10.1016/s0006-291x(84)80190-4. [DOI] [PubMed] [Google Scholar]
26.Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer’s disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82:4245–4249. doi: 10.1073/pnas.82.12.4245. [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Perlmutter LS, Barron E, Chui HC. Morphologic association between microglia and senile plaque amyloid in Alzheimer’s disease. Neurosci Lett. 1990;119:32–36. doi: 10.1016/0304-3940(90)90748-x. [DOI] [PubMed] [Google Scholar]
28.Dickson DW, Lee SC, Mattiace LA, Yen S-HC, Brosnan CF. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer’s disease. Glia. 1993;7:75–83. doi: 10.1002/glia.440070113. [DOI] [PubMed] [Google Scholar]
29.Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer’s disease. J Neuroimmunol. 1989;24:173–182. doi: 10.1016/0165-5728(89)90115-x. [DOI] [PubMed] [Google Scholar]
30.Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease. Neurobiol Aging. 2003;24:321–331. doi: 10.1016/s0197-4580(02)00090-8. [DOI] [PubMed] [Google Scholar]
31.Ginsberg SD, Crino PB, Lee VM-Y, Eberwine JH, Trojanowski JQ. Sequestration of RNA in Alzheimer’s disease neurofibrillary tangles and senile plaques. Ann Neurol. 1997;41:200–209. doi: 10.1002/ana.410410211. [DOI] [PubMed] [Google Scholar]
32.Iwatsubo T, Saido TC, Mann DMA, Lee VM-Y, Trojanowski JQ. Full-length amyloid-β(1–42(43)) and amino-terminally modified and truncated amyloid β42(43) deposit in diffuse plaques. Am J Pathol. 1996;149:1823–1830. [PMC free article] [PubMed] [Google Scholar]
33.Masliah E, Terry RD, Mallory N, Alford M, Hansen LA. Diffuse plaques do not accentuate synapse loss in Alzheimer’s disease. Am J Pathol. 1990;137:1293–1297. [PMC free article] [PubMed] [Google Scholar]
34.Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999;158:469–490. doi: 10.1006/exnr.1999.7086. [DOI] [PubMed] [Google Scholar]
35.Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology. 2003;60:1495–1500. doi: 10.1212/01.wnl.0000063311.58879.01. [DOI] [PubMed] [Google Scholar]
36.Bussiere T, Friend PD, Sadeghi N, Wicinski B, Lin Gl, Bouras C, et al. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer’s disease. Neuroscience. 2002;112:75–91. doi: 10.1016/s0306-4522(02)00056-8. [DOI] [PubMed] [Google Scholar]
37.Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Aβ causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675–688. doi: 10.1016/j.neuron.2005.01.040. [DOI] [PubMed] [Google Scholar]
38.Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, et al. Intraneuronal Alzheimer A(β)42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869–1879. doi: 10.1016/s0002-9440(10)64463-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Yang AJ, Knauer M, Burdick DA, Glabe C. Intracellular Aβ 1–42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J Biol Chem. 1995;270:14786–14792. doi: 10.1074/jbc.270.24.14786. [DOI] [PubMed] [Google Scholar]
40.Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004;165:1289–1300. doi: 10.1016/s0002-9440(10)63388-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998;150:296–304. doi: 10.1006/exnr.1997.6777. [DOI] [PubMed] [Google Scholar]
42.Hirayama A, Horikoshi Y, Maeda M, Ito M, Takashima S. Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome. Brain Dev. 2003;25:180–185. doi: 10.1016/s0387-7604(02)00209-7. [DOI] [PubMed] [Google Scholar]
43.Rovelet-Lecrux A, Hannequin D, Raux G, Meur NL, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer’s disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24–26. doi: 10.1038/ng1718. [DOI] [PubMed] [Google Scholar]
44.Selkoe DJ. Amyloid-β-protein and the genetics of Alzheimer’s disease. J Biol Chem. 1996;271:18295–18298. doi: 10.1074/jbc.271.31.18295. [DOI] [PubMed] [Google Scholar]
45.Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349:704–706. doi: 10.1038/349704a0. [DOI] [PubMed] [Google Scholar]
46.Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Aβ1–42/40 ratioin vitro and in vivo. Neuron. 1996;17:1005–1013. doi: 10.1016/s0896-6273(00)80230-5. [DOI] [PubMed] [Google Scholar]
47.Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373:523–527. doi: 10.1038/373523a0. [DOI] [PubMed] [Google Scholar]
48.Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102. doi: 10.1126/science.274.5284.99. [DOI] [PubMed] [Google Scholar]
49.Finckh U, Kuschel C, Anagnostouli M, Patsouris E, Pantes GV, Gatzonis S, et al. Novel mutations and repeated findings of mutations in familial Alzheimer’s disease. Neurogenetics. 2005;6:85–89. doi: 10.1007/s10048-005-0211-x. [DOI] [PubMed] [Google Scholar]
50.Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature. 1995;376:775–778. doi: 10.1038/376775a0. [DOI] [PubMed] [Google Scholar]
51.Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375:754–760. doi: 10.1038/375754a0. [DOI] [PubMed] [Google Scholar]
52.Kovacs DM, Fausett HJ, Page KJ, Kim T-W, Moir RD, Merriam DE, et al. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996;2:224–229. doi: 10.1038/nm0296-224. [DOI] [PubMed] [Google Scholar]
53.Lah JJ, Heilman CJ, Nash NR, Rees HD, Yi H, Counts SE, et al. Light and electron microscopic localization of presenilin-1 in primate brain. J Neurosci. 1997;17:1971–1980. doi: 10.1523/JNEUROSCI.17-06-01971.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
54.Iwatsubo T. The gamma-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol. 2004;14:379–383. doi: 10.1016/j.conb.2004.05.010. [DOI] [PubMed] [Google Scholar]
55.Pasternak SH, Bagshaw RD, Guiral M, Zhang S, Ackerley CA, Pak BJ, et al. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J Biol Chem. 2003;278:26687–26894. doi: 10.1074/jbc.m304009200. [DOI] [PubMed] [Google Scholar]
56.Duff K, Eckman C, Zehr C, Yu X, Prada C-M, Perez-tur J, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710–713. doi: 10.1038/383710a0. [DOI] [PubMed] [Google Scholar]
57.Citron M, Westaway D, Xia W, Carlson G, Levesque G, Johnson-Wood K, et al. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67–72. doi: 10.1038/nm0197-67. [DOI] [PubMed] [Google Scholar]
58.Iwatsubo T, Okada A, Suzuki N, Mizusawa N, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43) Neuron. 1994;13:45–53. doi: 10.1016/0896-6273(94)90458-8. [DOI] [PubMed] [Google Scholar]
59.Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry. 1993;32:4693–4697. doi: 10.1021/bi00069a001. [DOI] [PubMed] [Google Scholar]
60.Jin L-W, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-{β} precursor protein in neurons with Niemann-Pick Type C defects is associated with endosomal abnormalities. Am J Pathol. 2004;164:975–985. doi: 10.1016/s0002-9440(10)63185-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
61.Hauser ER, Pericak-Vance MA. Genetic analysis for common complex disease. Am Heart J. 2000;140:S36–S44. doi: 10.1067/mhj.2000.108946. [DOI] [PubMed] [Google Scholar]
62.Bently DR, Dunham I. Mapping human chromosomes. Curr Opin Genet Dev. 1995;5:328–334. doi: 10.1016/0959-437x(95)80047-6. [DOI] [PubMed] [Google Scholar]
63.Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, et al. Identification of novel genes in late-onset Alzheimer’s disease. Exp Gerontol. 2000;35:1343–1352. doi: 10.1016/s0531-5565(00)00196-0. [DOI] [PubMed] [Google Scholar]
64.Olson JM, Goddard KA, Dudek DM. A second locus for verylate-onset Alzheimer’s disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum Genet. 2002;71:154–161. doi: 10.1086/341034. [DOI] [PMC free article] [PubMed] [Google Scholar]
65.Grupe A, Li Y, Rowland C, Nowotny P, Hinrichs AL, Smemo S, et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer’s disease. Am J Hum Genet. 2006;78:78–88. doi: 10.1086/498851. [DOI] [PMC free article] [PubMed] [Google Scholar]
66.Schmitz C, Rutten BPF, Pielen A, Schafer S, Wirths O, Tremp G, et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer’s disease. Am J Pathol. 2004;164:1495–1502. doi: 10.1016/S0002-9440(10)63235-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
67.Couchie D, Mavilia C, Georgieff IS, Liem RK, Shelanski ML, Nunez J. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci USA. 1992;89:4378–4381. doi: 10.1073/pnas.89.10.4378. [DOI] [PMC free article] [PubMed] [Google Scholar]
68.Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol. 1985;101:1371–1378. doi: 10.1083/jcb.101.4.1371. [DOI] [PMC free article] [PubMed] [Google Scholar]
69.Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739:240–250. doi: 10.1016/j.bbadis.2004.08.007. [DOI] [PubMed] [Google Scholar]
70.Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8:393–399. doi: 10.1002/j.1460-2075.1989.tb03390.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
71.Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989;3:519–526. doi: 10.1016/0896-6273(89)90210-9. [DOI] [PubMed] [Google Scholar]
72.Goode BL, Feinstein SC. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol. 1994;124:769–782. doi: 10.1083/jcb.124.5.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
73.Ginsberg SD, Che S, Counts SE, Mufson EJ. Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. J Neurochem. 2006;96:1401–1408. doi: 10.1111/j.1471-4159.2005.03641.x. [DOI] [PubMed] [Google Scholar]
74.Drecshel DN, Hyman AA, Cobb MH, Kirschner M. Modulation of the dynamic instability of tubulin assembly by the microtubule associated protein tau. Mol Biol Cell. 1992;3:1147–1154. doi: 10.1091/mbc.3.10.1141. [DOI] [PMC free article] [PubMed] [Google Scholar]
75.Kosik KS, Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim Biophys Acta. 2005;1739:298–310. doi: 10.1016/j.bbadis.2004.10.011. [DOI] [PubMed] [Google Scholar]
76.Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem. 1995;270:823–829. doi: 10.1074/jbc.270.2.823. [DOI] [PubMed] [Google Scholar]
77.Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, et al. Tau is a candidate gene for chromosome 17 fronto-temporal dementia. Ann Neurol. 1998;43:815–825. doi: 10.1002/ana.410430617. [DOI] [PubMed] [Google Scholar]
78.Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–705. doi: 10.1038/31508. [DOI] [PubMed] [Google Scholar]
79.Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–1159. doi: 10.1146/annurev.neuro.24.1.1121. [DOI] [PubMed] [Google Scholar]
80.Ingram EM, Spillantini MG. Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol Med. 2002;8:555–562. doi: 10.1016/s1471-4914(02)02440-1. [DOI] [PubMed] [Google Scholar]
81.Mott RT, Dickson DW, Trojanowski JQ, Zhukareva V, Lee VM, Forman M, et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol. 2005;64:420–428. doi: 10.1093/jnen/64.5.420. [DOI] [PubMed] [Google Scholar]
82.Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol. 1998;8:387–402. doi: 10.1111/j.1750-3639.1998.tb00162.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
83.Bergmann M, Kuchelmeister K, Schmid KW, Kretzschmar HA, Schroder R. Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study. Acta Neuropathol (Berl) 1996;92:170–179. doi: 10.1007/s004010050505. [DOI] [PubMed] [Google Scholar]
84.Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282:1914–1917. doi: 10.1126/science.282.5395.1914. [DOI] [PubMed] [Google Scholar]
85.Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde Y-A, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582–590. doi: 10.1046/j.1471-4159.2003.01879.x. [DOI] [PubMed] [Google Scholar]
86.Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446–5454. doi: 10.1523/JNEUROSCI.4637-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
87.Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem. 2001;276:529–534. doi: 10.1074/jbc.M006531200. [DOI] [PubMed] [Google Scholar]
88.Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J Neurosci. 2005;25:10637–10647. doi: 10.1523/JNEUROSCI.3279-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
89.Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, et al. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol. 2005;166:521–531. doi: 10.1016/S0002-9440(10)62274-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
90.Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer’s disease. Neurobiol Aging. 2005;26:355–361. doi: 10.1016/j.neurobiolaging.2004.09.003. [DOI] [PubMed] [Google Scholar]
91.Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA. 1995;92:4725–4727. doi: 10.1073/pnas.92.11.4725. [DOI] [PMC free article] [PubMed] [Google Scholar]
92.Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, et al. ApoE-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiative. Neurology. 1997;48:139–147. doi: 10.1212/wnl.48.1.139. [DOI] [PubMed] [Google Scholar]
93.Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, et al. Apolipoprotein E s4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology. 2003;60:246–252. doi: 10.1212/01.wnl.0000042478.08543.f7. [DOI] [PubMed] [Google Scholar]
94.Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–923. doi: 10.1126/science.8346443. [DOI] [PubMed] [Google Scholar]
95.Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer’s disease. Nat Genet. 1994;7:180–184. doi: 10.1038/ng0694-180. [DOI] [PubMed] [Google Scholar]
96.Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–630. doi: 10.1126/science.3283935. [DOI] [PubMed] [Google Scholar]
97.Lahiri DK. Apolipoprotein E as a target for developing new therapeutics for Alzheimer’s disease based on studies from protein, RNA, and regulatory region of the gene. J Mol Neurosci. 2004;23:225–233. doi: 10.1385/JMN:23:3:225. [DOI] [PubMed] [Google Scholar]
98.Benzing WC, Mufson EJ. Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to tau and PHF in Alzheimer’s disease. Exp Neurol. 1995;132:162–171. doi: 10.1016/0014-4886(95)90021-7. [DOI] [PubMed] [Google Scholar]
99.Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-M, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloidβ peptide: isoform-specific effects and implications for late-onset Alzheimer’s disease. Proc Natl Acad Sci USA. 1993;90:8098–8102. doi: 10.1073/pnas.90.17.8098. [DOI] [PMC free article] [PubMed] [Google Scholar]
100.Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer’s fibril formation by apolipoprotein Ein vitro. Am J Pathol. 1994;145:1030–1035. [PMC free article] [PubMed] [Google Scholar]
101.Sanan DA, Weisgraber K, Russell SJ, Mahley RW, Huang D, Saunders A, et al. Apolipoprotein E associates with Aβ amyloid peptide to form novel monofibrils: isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994;94:860–869. doi: 10.1172/JCI117407. [DOI] [PMC free article] [PubMed] [Google Scholar]
102.Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong L-M, Jakes R, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer’s disease. Proc Natl Acad Sci USA. 1994;91:11183–11186. doi: 10.1073/pnas.91.23.11183. [DOI] [PMC free article] [PubMed] [Google Scholar]
103.Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163–166. doi: 10.1016/0006-8993(91)91092-f. [DOI] [PubMed] [Google Scholar]
104.Bao F, Arai H, Matsushita S, Higuchi S, Sasaki H. Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. NeuroReport. 1996;7:1733–1739. doi: 10.1097/00001756-199607290-00008. [DOI] [PubMed] [Google Scholar]
105.Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PN, Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci. 2003;23:5219–5226. doi: 10.1523/JNEUROSCI.23-12-05219.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
106.Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum Mol Genet. 2004;13:1225–1240. doi: 10.1093/hmg/ddh140. [DOI] [PubMed] [Google Scholar]
107.Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA. 2004;101:2173–2178. doi: 10.1073/pnas.0308512100. [DOI] [PMC free article] [PubMed] [Google Scholar]
108.Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res. 2002;70:462–473. doi: 10.1002/jnr.10351. [DOI] [PubMed] [Google Scholar]
109.Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer’s disease. DNA Cell Biol. 2001;20:683–695. doi: 10.1089/10445490152717541. [DOI] [PubMed] [Google Scholar]
110.Lukiw WJ. Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem Res. 2004;29:1287–1297. doi: 10.1023/b:nere.0000023615.89699.63. [DOI] [PubMed] [Google Scholar]
111.Minagar A, Shapshak P, Duran EM, Kablingerm AS, Alexander JS, Kelley RE, et al. HIV-associated dementia, Alzheimer’s disease, multiple sclerosis, and schizophrenia: gene expression review. J Neurol Sci. 2004;224:3–17. doi: 10.1016/j.jns.2004.06.007. [DOI] [PubMed] [Google Scholar]
112.Roy Walker P, Smith B, Liu QY, Fazel Famili A, Valdes JJ, Liu Z, et al. Data mining of gene expression changes in Alzheimer brain. Artif Intell Med. 2004;31:137–154. doi: 10.1016/j.artmed.2004.01.008. [DOI] [PubMed] [Google Scholar]
113.Katsel PL, Davis KL, Haroutunian V. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer’s disease. Int Rev Neurobiol. 2005;63:41–82. doi: 10.1016/S0074-7742(05)63003-6. [DOI] [PubMed] [Google Scholar]
114.Marcotte ER, Srivastava LK, Quirion R. cDNA microarray and proteomic approaches in the study of brain diseases: focus on schizophrenia and Alzheimer’s disease. Pharmacol Ther. 2003;100:63–74. doi: 10.1016/s0163-7258(03)00086-x. [DOI] [PubMed] [Google Scholar]
115.Ricciarelli R, d’Abramo C, Massone S, Marinari U, Pronzato M, Tabaton M. Microarray analysis in Alzheimer’s disease and normal aging. IUBMB Life. 2004;56:349–354. doi: 10.1080/15216540412331286002. [DOI] [PubMed] [Google Scholar]
116.Blalock EM, Chen KC, Stromberg AJ, Norris CM, Kadish I, Kraner SD, et al. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer’s disease: statistical reliability and functional correlation. Aging Res Rev. 2005;4:481–512. doi: 10.1016/j.arr.2005.06.006. [DOI] [PubMed] [Google Scholar]
117.Ginsberg SD. RNA amplification strategies for small sample populations. Methods. 2005;37:229–237. doi: 10.1016/j.ymeth.2005.09.003. [DOI] [PubMed] [Google Scholar]
118.Ginsberg SD, Hemby SE, Mufson EJ, Martin LJ. Cell and tissue microdissection in combination with genomic and proteomic applications. In: Zaborszky L, Wouterlood F, Lanciego JL, editors. Neuroanatomical tract tracing 3: Molecules-neurons-systems. New York: Springer/Kluwer/Plenum; 2006. pp. 109–141. [Google Scholar]
119.Counts SE, Chen EY, Che S, Ikonomovic MD, Wuu J, Ginsberg SD, et al. Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2006;21:205–214. doi: 10.1159/000090906. [DOI] [PubMed] [Google Scholar]
120.Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer’s disease. J Neurochem. 2006;97:475–487. doi: 10.1111/j.1471-4159.2006.03764.x. [DOI] [PubMed] [Google Scholar]
121.Fasulo WH, Hemby SE. Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration. J Neurochem. 2003;87:205–219. doi: 10.1046/j.1471-4159.2003.01986.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
122.Tang WX, Fasulo WH, Mash DC, Hemby SE. Molecular profiling of midbrain dopamine regions in cocaine overdose victims. J Neurochem. 2003;85:911–924. doi: 10.1046/j.1471-4159.2003.01740.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
123.Greene JG, Dingledine R, Greenamyre JT. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis. 2005;18:19–31. doi: 10.1016/j.nbd.2004.10.003. [DOI] [PubMed] [Google Scholar]
124.Kamme F, Salunga R, Yu J, Tran DT, Zhu J, Luo L, et al. Single-cell microarray analysis in hippocampus CA1: demonstration and validation of cellular heterogeneity. J Neurosci. 2003;23:3607–3615. doi: 10.1523/JNEUROSCI.23-09-03607.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
125.Luo L, Salunga RC, Guo H, Bittner A, Joy KC, Galindo JE, et al. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med. 1999;5:117–122. doi: 10.1038/4806. [DOI] [PubMed] [Google Scholar]
126.Ginsberg SD, Che S. Combined histochemical staining, RNA amplification, regional, and single cell analysis within the hippocampus. Lab Invest. 2004;84:952–962. doi: 10.1038/labinvest.3700110. [DOI] [PubMed] [Google Scholar]
127.Vincent VA, DeVoss JJ, Ryan HS, Murphy GM. Analysis of neuronal gene expression with laser capture microdissection. J Neurosci Res. 2002;69:578–586. doi: 10.1002/jnr.10329. [DOI] [PubMed] [Google Scholar]
128.Ginsberg SD, Elarova I, Ruben M, Tan F, Counts SE, Eberwine JH, et al. Single cell gene expression analysis: implications for neurodegenerative and neuropsychiatrie disorders. Neurochem Res. 2004;29:1054–1065. doi: 10.1023/b:nere.0000023593.77052.f7. [DOI] [PubMed] [Google Scholar]
129.Ginsberg SD, Che S. Expression profile analysis within the human hippocampus: comparison of CA1 and CA3 pyramidal neurons. J Comp Neurol. 2005;487:107–118. doi: 10.1002/cne.20535. [DOI] [PubMed] [Google Scholar]
130.Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, et al. Laser capture microdissection: molecular analysis of tissue. Science. 1997;278:1481–1483. doi: 10.1126/science.278.5342.1481. [DOI] [PubMed] [Google Scholar]
131.Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science. 1996;274:998–1001. doi: 10.1126/science.274.5289.998. [DOI] [PubMed] [Google Scholar]
132.Ginsberg SD. Glutamatergic neurotransmission expression profiling in the mouse hippocampus after perforant-path transection. Am J Geriatr Psychiatry. 2005;13:1052–1061. doi: 10.1176/appi.ajgp.13.12.1052. [DOI] [PubMed] [Google Scholar]
133.Ginsberg SD, Che S. RNA amplification in brain tissues. Neurochem Res. 2002;27:981–992. doi: 10.1023/a:1020944502581. [DOI] [PubMed] [Google Scholar]
134.Ginsberg SD, Crino PB, Hemby SE, Weingarten JA, Lee VM-Y, Eberwine JH, et al. Predominance of neuronal mRNAs in individual Alzheimer’s disease senile plaques. Ann Neurol. 1999;45:174–181. [PubMed] [Google Scholar]
135.Ginsberg SD, Hemby SE, Lee VM-Y, Eberwine JH, Trojanowski JQ. Expression profile of transcripts in Alzheimer’s disease tangle-bearing CA1 neurons. Ann Neurol. 2000;48:77–87. [PubMed] [Google Scholar]
136.Hemby SE, Ginsberg SD, Brunk B, Arnold SE, Trojanowski JQ, Eberwine JH. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry. 2002;59:631–640. doi: 10.1001/archpsyc.59.7.631. [DOI] [PubMed] [Google Scholar]
137.Hemby SE, Trojanowski JQ, Ginsberg SD. Neuron-specific age-related decreases in dopamine receptor subtype mRNAs. J Comp Neurol. 2003;456:176–183. doi: 10.1002/cne.10525. [DOI] [PMC free article] [PubMed] [Google Scholar]
138.Mufson EJ, Counts SE, Ginsberg SD. Single cell gene expression profiles of nucleus basalis cholinergic neurons in Alzheimer’s disease. Neurochem Res. 2002;27:1035–1048. doi: 10.1023/a:1020952704398. [DOI] [PubMed] [Google Scholar]
139.Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, et al. Analysis of gene expression in single live neurons. Proc Natl Acad Sci USA. 1992;89:3010–3014. doi: 10.1073/pnas.89.7.3010. [DOI] [PMC free article] [PubMed] [Google Scholar]
140.Eberwine J, Kacharmina JE, Andrews C, Miyashiro K, McIntosh T, Becker K, et al. mRNA expression analysis of tissue sections and single cells. J Neurosci. 2001;21:8310–8314. doi: 10.1523/JNEUROSCI.21-21-08310.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
141.Eberwine J, Belt B, Kacharmina JE, Miyashiro K. Analysis of subcellularly localized mRNAs usingin situ hybridization, mRNA amplification, and expression profiling. Neurochem Res. 2002;27:1065–1077. doi: 10.1023/a:1020956805307. [DOI] [PubMed] [Google Scholar]
142.van Gelder R, von Zastrow M, Yool A, Dement W, Barchas J, Eberwine J. Amplified RNA (aRNA) synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA. 1990;87:1663–1667. doi: 10.1073/pnas.87.5.1663. [DOI] [PMC free article] [PubMed] [Google Scholar]
143.Cheetham JE, Coleman PD, Chow N. Isolation of single immunohistochemically identified whole neuronal cell bodies from post-mortem human brain for simultaneous analysis of multiple gene expression. J Neurosci Methods. 1997;77:43–48. doi: 10.1016/s0165-0270(97)00109-x. [DOI] [PubMed] [Google Scholar]
144.Chow N, Cox C, Callahan LM, Weimer JM, Guo L, Coleman PD. Expression profiles of multiple genes in single neurons of Alzheimer’s disease. Proc Natl Acad Sci USA. 1998;95:9620–9625. doi: 10.1073/pnas.95.16.9620. [DOI] [PMC free article] [PubMed] [Google Scholar]
145.Mufson EJ, Counts SE, Che S, Ginsberg SD. Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease.Prog Neurobiol (in press). [DOI] [PubMed]
146.Ginsberg SD, Mimics K. Functional genomics methodologies.Prog Neurobiol (in press).
147.Dafforn A, Chen P, Deng G, Herrler M, Iglehart D, Koritala S, et al. Linear mRNA amplification from as little as 5 ng total RNA for global gene expression analysis. BioTechniques. 2004;37:854–857. doi: 10.2144/04375PF01. [DOI] [PubMed] [Google Scholar]
148.Kurn N, Chen P, Heath JD, Kopf-Sill A, Stephens KM, Wang S. Novel isothermal, linear nucleic acid amplification systems for highly multiplexed applications. Clin Chem. 2005;51:1973–1981. doi: 10.1373/clinchem.2005.053694. [DOI] [PubMed] [Google Scholar]
149.Che S, Ginsberg SD. Amplification of transcripts using terminal continuation. Lab Invest. 2004;84:131–137. doi: 10.1038/labinvest.3700005. [DOI] [PubMed] [Google Scholar]
150.Che S, Ginsberg SD. RNA amplification methodologies. In: Trends in RNA research. Hauppauge, NY: Nova Science Publishing (in press).
151.Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999;21:33–37. doi: 10.1038/4462. [DOI] [PubMed] [Google Scholar]
152.Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol. 1999;303:179–205. doi: 10.1016/s0076-6879(99)03014-1. [DOI] [PubMed] [Google Scholar]
153.Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467–470. doi: 10.1126/science.270.5235.467. [DOI] [PubMed] [Google Scholar]
154.Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high density oligonucleotide arrays. Nat Biotechnol. 1996;14:1675–1680. doi: 10.1038/nbt1296-1675. [DOI] [PubMed] [Google Scholar]
155.Olson NE. The microarray data analysis process: from raw data to biological significance. NeuroRx. 2006;3:371–381. doi: 10.1016/j.nurx.2006.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
156.Almudevar A, Klebanov LB, Qiu X, Salzman P, Yakovlev AY. Utility of correlation measures in analysis of gene expression. NeuroRx. 2006;3:382–393. doi: 10.1016/j.nurx.2006.05.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
157.Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999;19:1720–1730. doi: 10.1128/mcb.19.3.1720. [DOI] [PMC free article] [PubMed] [Google Scholar]
158.Ginsberg SD, Galvin JE, Chiu T-S, Lee VM-Y, Masliah E, Trojanowski JQ. RNA sequestration to pathological lesions of neurodegenerative disorders. Acta Neuropathol. 1998;96:487–494. doi: 10.1007/s004010050923. [DOI] [PubMed] [Google Scholar]
159.Topaloglu H, Samat HB. Acridine orange-RNA fluorescence maturing neurons in the perinatal rat brain. Anat Rec. 1989;224:88–93. doi: 10.1002/ar.1092240111. [DOI] [PubMed] [Google Scholar]
160.Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 1997;77:1037–1048. doi: 10.1016/s0306-4522(96)00545-3. [DOI] [PubMed] [Google Scholar]
161.Eikelenboom P, Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer’s disease. Neurobiol Aging. 1996;17:673–680. doi: 10.1016/0197-4580(96)00108-x. [DOI] [PubMed] [Google Scholar]
162.Sarnat HB, Curry B, Rewcastle NB, Trevenen CL. Gliosis and glioma distinguished by acridine orange. Can J Neurol Sci. 1987;14:31–35. doi: 10.1017/s0317167100026135. [DOI] [PubMed] [Google Scholar]
163.Burbach GJ, Dehn D, Nagel B, Del Turco D, Deller T. Laser microdissection of immunolabeled astrocytes allows quantification of astrocytic gene expression. J Neurosci Methods. 2004;138:141–148. doi: 10.1016/j.jneumeth.2004.03.022. [DOI] [PubMed] [Google Scholar]
164.Burbach GJ, Dehn D, Del Turco D, Staufenbiel M, Deller T. Laser microdissection reveals regional and cellular differences in GFAP mRNA upregulation following brain injury, axonal denervation, and amyloid plaque deposition. Glia. 2004;48:76–84. doi: 10.1002/glia.20057. [DOI] [PubMed] [Google Scholar]
165.Harrison PJ, Barton AJ, Najlerahim A, McDonald B, Pearson RC. Regional and neuronal reductions of polyadenylated messenger RNA in Alzheimer’s disease. Psychol Med. 1991;21:855–866. doi: 10.1017/s0033291700029858. [DOI] [PubMed] [Google Scholar]
166.Griffin WS, Ling C, White CL, Morrison-Bogorad M. Polyadenylated messenger RNA in paired helical filament-immunoreactive neurons in Alzheimer’s disease. Alzheimer Dis Assoc Dis. 1990;4:69–78. [PMC free article] [PubMed] [Google Scholar]
167.Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci. 2005;22:1942–1950. doi: 10.1111/j.1460-9568.2005.04391.x. [DOI] [PubMed] [Google Scholar]
168.Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp Neurol. 2001;168:402–412. doi: 10.1006/exnr.2001.7630. [DOI] [PubMed] [Google Scholar]
169.Goedert M, Jakes R, Qi Z, Wang JH, Cohen P. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates t protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J Neurochem. 1995;65:2804–2807. doi: 10.1046/j.1471-4159.1995.65062804.x. [DOI] [PubMed] [Google Scholar]
170.Joyce JN, Kaeger C, Ryoo H, Goldsmith S. Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer’s disease. Neurosci Lett. 1993;154:171–174. doi: 10.1016/0304-3940(93)90199-u. [DOI] [PubMed] [Google Scholar]
171.Ryoo HL, Joyce JN. Loss of dopamine D2 receptors varies along the rostrocaudal axis of the hippocampal complex in Alzheimer’s disease. J Comp Neurol. 1994;348:94–110. doi: 10.1002/cne.903480105. [DOI] [PubMed] [Google Scholar]
172.Rinne JO, Lonnberg P, Marjamaki P. Age-dependent decline in human brain dopamine D1 and D2 receptors. Brain Res. 1990;508:349–352. doi: 10.1016/0006-8993(90)90423-9. [DOI] [PubMed] [Google Scholar]
173.Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol. 1998;44:143–147. doi: 10.1002/ana.410440125. [DOI] [PubMed] [Google Scholar]
174.Amenta F, Mignini F, Ricci A, Sabbatini M, Tomassoni D, Tayebati SK. Age-related changes of dopamine receptors in the rat hippocampus: a light microscope autoradiography study. Mech Aging Dev. 2001;122:2071–2083. doi: 10.1016/s0047-6374(01)00317-7. [DOI] [PubMed] [Google Scholar]
175.Gutala RV, Reddy PH. The use of real-time PCR analysis in a gene expression study of Alzheimer’s disease post-mortem brains. J Neurosci Methods. 2004;132:101–107. doi: 10.1016/j.jneumeth.2003.09.005. [DOI] [PubMed] [Google Scholar]
176.Callahan LM, Vaules WA, Coleman PD. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer’s disease neurons containing neurofibrillary tangles. J Neuropathol Exp Neurol. 1999;58:275–287. doi: 10.1097/00005072-199903000-00007. [DOI] [PubMed] [Google Scholar]
177.Heffeman JM, Eastwood SL, Nagy Z, Sanders MW, McDonald B, Harrison PJ. Temporal cortex synaptophysin mRNA is reduced in Alzheimer’s disease and is negatively correlated with the severity of dementia. Exp Neurol. 1998;150:235–239. doi: 10.1006/exnr.1997.6772. [DOI] [PubMed] [Google Scholar]
178.Shimohama S, Kamiya S, Taniguchi T, Akagawa K, Kimura J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer’s disease. Biochem Biophys Res Commun. 1997;236:239–242. doi: 10.1006/bbrc.1997.6940. [DOI] [PubMed] [Google Scholar]
179.Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer’s disease. J Neuropathol Exp Neurol. 1997;56:933–944. doi: 10.1097/00005072-199708000-00011. [DOI] [PubMed] [Google Scholar]
180.Sze CI, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer’s disease brains. J Neurol Sci. 2000;175:81–90. doi: 10.1016/s0022-510x(00)00285-9. [DOI] [PubMed] [Google Scholar]
181.Cataldo AM, Paskevich PA, Kominami E, Nixon RA. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer’s disease. Proc Nail Acad Sci USA. 1991;88:10998–11002. doi: 10.1073/pnas.88.24.10998. [DOI] [PMC free article] [PubMed] [Google Scholar]
182.Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, et al. Gene expression and cellular content of cathepsin D in Alzheimer’s disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron. 1995;14:671–680. doi: 10.1016/0896-6273(95)90324-0. [DOI] [PubMed] [Google Scholar]
183.Cataldo AM, Bamett JL, Picroni C, Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer’s disease: neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J Neurosci. 1997;17:6142–6151. doi: 10.1523/JNEUROSCI.17-16-06142.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
184.Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, et al. Macroautophagy: a novel β-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol. 2005;171:87–98. doi: 10.1083/jcb.200505082. [DOI] [PMC free article] [PubMed] [Google Scholar]
185.Nixon RA. Endosome function and dysfunction in Alzheimer’s disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373–382. doi: 10.1016/j.neurobiolaging.2004.09.018. [DOI] [PubMed] [Google Scholar]
186.Cataldo AM, Hamilton DJ, Bamett JL, Paskevich PA, Nixon RA. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer’s disease. J Neurosci. 1996;16:186–199. doi: 10.1523/JNEUROSCI.16-01-00186.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
187.Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol. 1983;214:170–197. doi: 10.1002/cne.902140206. [DOI] [PubMed] [Google Scholar]
188.Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–414. doi: 10.1126/science.7046051. [DOI] [PubMed] [Google Scholar]
189.Baxter MG, Chiba AA. Cognitive functions of the basal fore-brain. Curr Opin Neurobiol. 1999;9:178–183. doi: 10.1016/s0959-4388(99)80024-5. [DOI] [PubMed] [Google Scholar]
190.Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2:1403–1403. doi: 10.1016/s0140-6736(76)91936-x. [DOI] [PubMed] [Google Scholar]
191.Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, et al. Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits. J Neurochem. 1995;64:749–760. doi: 10.1046/j.1471-4159.1995.64020749.x. [DOI] [PubMed] [Google Scholar]
192.Auld DS, Komecook TJ, Bastianetto S, Quirion R. Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68:209–245. doi: 10.1016/s0301-0082(02)00079-5. [DOI] [PubMed] [Google Scholar]
193.Galvin JE, Ginsberg SD. Expression profiling in the aging brain: a perspective. Aging Res Rev. 2005;4:529–547. doi: 10.1016/j.arr.2005.06.009. [DOI] [PubMed] [Google Scholar]
194.Galvin JE, Ginsberg SD. Expression profiling and pharmacotherapeutic development in the central nervous system. Alzheimer Dis Assoc Disord. 2004;18:264–269. [PubMed] [Google Scholar]
195.Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol. 2004;55:815–828. doi: 10.1002/ana.20100. [DOI] [PubMed] [Google Scholar]
196.Counts SE, Mufson EJ. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer’s disease. J Neuropathol Exp Neurol. 2005;64:263–272. doi: 10.1093/jnen/64.4.263. [DOI] [PubMed] [Google Scholar]
197.Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer’s disease. J Comp Neurol. 2000;427:19–30. doi: 10.1002/1096-9861(20001106)427:1<19::aid-cne2>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
198.Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198–205. doi: 10.1212/wnl.59.2.198. [DOI] [PubMed] [Google Scholar]
199.King ME, Gamblin TC, Kuret J, Binder LI. Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem. 2000;74:1749–1757. doi: 10.1046/j.1471-4159.2000.0741749.x. [DOI] [PubMed] [Google Scholar]
200.Levy SF, Leboeuf AC, Massie MR, Jordan MA, Wilson L, Feinstein SC. Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners: implications for neurodegeneration. J Biol Chem. 2005;280:13520–13528. doi: 10.1074/jbc.M413490200. [DOI] [PubMed] [Google Scholar]
201.Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA. Over-expression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer’s disease. Ann Neurol. 1999;46:325–332. doi: 10.1002/1531-8249(199909)46:3<325::aid-ana8>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
202.de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol. 2003;29:288–302. doi: 10.1046/j.1365-2990.2003.00463.x. [DOI] [PubMed] [Google Scholar]
203.Arai T, Ikeda K, Akiyama H, Tsuchiya K, Iritani S, Ishiguro K, et al. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berl) 2003;105:489–498. doi: 10.1007/s00401-003-0671-8. [DOI] [PubMed] [Google Scholar]
204.Fujino Y, Wang DS, Thomas N, Espinoza M, Davies P, Dickson DW. Increased frequency of argyrophilic grain disease in Alzheimer disease with 4R tau-specific immunohistochemistry. J Neuropathol Exp Neurol. 2005;64:209–214. doi: 10.1093/jnen/64.3.209. [DOI] [PubMed] [Google Scholar]
205.Zhukareva V, Shah K, Uryu K, Braak H, Del Tredici K, Sundarraj S, et al. Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer’s disease, and Pick’s disease: a comparative study. Am J Pathol. 2002;161:1135–1141. doi: 10.1016/s0002-9440(10)64390-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
206.Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat. 2003;26:233–242. doi: 10.1016/s0891-0618(03)00068-1. [DOI] [PubMed] [Google Scholar]
207.Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217–1281. doi: 10.1146/annurev.neuro.24.1.1217. [DOI] [PubMed] [Google Scholar]
208.Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer’s disease. Ann Neurol. 2004;56:520–531. doi: 10.1002/ana.20233. [DOI] [PubMed] [Google Scholar]
209.Colantuoni C, Purcell AE, Bouton CM, Pevsner J. High throughput analysis of gene expression in the human brain. J Neurosci Res. 2000;59:1–10. doi: 10.1002/(sici)1097-4547(20000101)59:1<1::aid-jnr1>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
210.Serafini T. Of neurons and gene chips. Curr Opin Neurobiol. 1999;9:641–644. doi: 10.1016/s0959-4388(99)00022-7. [DOI] [PubMed] [Google Scholar]

[CR1] 1.Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA. 1989;262:2256–2551. [PubMed] [Google Scholar]

[CR2] 2.Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer’s disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001;15:169–173. doi: 10.1097/00002093-200110000-00002. [DOI] [PubMed] [Google Scholar]

[CR3] 3.Ginsberg SD, Schmidt ML, Crino PB, Eberwine JH, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer’s disease and related disorders. In: Peters A, Morrison JH, editors. Cerebral cortex: neurodegenerative and age-related changes in structure and function of cerebral cortex. New York: Kluwer Academic/Plenum; 1999. pp. 203–653. [Google Scholar]

[CR4] 4.Selkoe DJ. Alzheimer’s disease: genotypes, phenotypes, and treatments. Science. 1997;275:630–631. doi: 10.1126/science.275.5300.630. [DOI] [PubMed] [Google Scholar]

[CR5] 5.Trojanowski JQ, Lee VM. The Alzheimer’s brain: finding out what’s broken tells us how to fix it. Am J Pathol. 2005;167:1183–1188. doi: 10.1016/s0002-9440(10)61206-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR6] 6.Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. NGF family of neurotrophins and their receptors: early involvement in the progression of Alzheimer’s disease. In: Dawbarn D, Allen SJ, editors. Neurobiology of Alzheimer’s disease. 3rd ed. Oxford, UK: Oxford University Press; 2006. [Google Scholar]

[CR7] 7.Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer’s disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol. 1989;105:221–232. doi: 10.1016/0014-4886(89)90124-6. [DOI] [PubMed] [Google Scholar]

[CR8] 8.Mufson EJ, Bothwell M, Hersh LB, Kordower JH. Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: colocalization with cholinergic neurons. J Comp Neurol. 1989;285:196–217. doi: 10.1002/cne.902850204. [DOI] [PubMed] [Google Scholar]

[CR9] 9.Whitehouse PJ, Rice DL, Struble RG, Clark AW, Coyle JT, Delong MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237–1239. doi: 10.1126/science.7058341. [DOI] [PubMed] [Google Scholar]

[CR10] 10.Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2:1403–1403. doi: 10.1016/s0140-6736(76)91936-x. [DOI] [PubMed] [Google Scholar]

[CR11] 11.Hyman BT, van Hoesen GW, Damasio AR, Barnes CL. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168–1170. doi: 10.1126/science.6474172. [DOI] [PubMed] [Google Scholar]

[CR12] 12.Hyman BT, van Hoesen GW, Damasio AR. Memory-related neural systems in Alzheimer’s disease: an anatomic study. Neurology. 1990;40:1721–1730. doi: 10.1212/wnl.40.11.1721. [DOI] [PubMed] [Google Scholar]

[CR13] 13.Hof PR, Morrison JH. The aging brain: morphomolecular senescence of cortical circuits. Trends Neurosci. 2004;27:607–613. doi: 10.1016/j.tins.2004.07.013. [DOI] [PubMed] [Google Scholar]

[CR14] 14.Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer’s disease. J Neuropathol Exp Neurol. 1997;56:1095–1097. doi: 10.1097/00005072-199710000-00002. [DOI] [PubMed] [Google Scholar]

[CR15] 15.Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II. Standardization of the neuro-pathologic assessment of Alzheimer’s disease. Neurology. 1991;41:479–486. doi: 10.1212/wnl.41.4.479. [DOI] [PubMed] [Google Scholar]

[CR16] 16.Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol Aging. 1998;19:173–189. doi: 10.1016/s0197-4580(98)00052-9. [DOI] [PubMed] [Google Scholar]

[CR17] 17.Alzheimer A. Uber eine eigenartige Erkrangkung der Hirnrinde. All Z Psychiatr. 1907;64:146–148. [Google Scholar]

[CR18] 18.Skovronsky DM, Lee VM-Y, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis. 2006;1:151–170. doi: 10.1146/annurev.pathol.1.110304.100113. [DOI] [PubMed] [Google Scholar]

[CR19] 19.Cohen AS, Connors LH. The pathogenesis and biochemistry of amyloidosis. J Pathol. 1987;151:1–10. doi: 10.1002/path.1711510102. [DOI] [PubMed] [Google Scholar]

[CR20] 20.Iwai A, Yoshimoto M, Masliah E, Saitoh T. Non-Aβ component of Alzheimer’s disease amyloid (NAC) is amyloidogenic. Biochemistry. 1995;34:10139–10145. doi: 10.1021/bi00032a006. [DOI] [PubMed] [Google Scholar]

[CR21] 21.Masliah E, Iwai A, Mallory M, Ueda K, Saitoh T. Altered pre-synaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer’s disease. Am J Pathol. 1996;148:201–210. [PMC free article] [PubMed] [Google Scholar]

[CR22] 22.Schmidt ML, DiDario AG, Otvos L, Hoshi M, Kant JA, Lee VM-Y, et al. Plaque-associated neuronal proteins: a recurrent motif in neuritic amyloid deposits throughout diverse cortical areas of the Alzheimer’s disease brain. Exp Neurol. 1994;130:311–322. doi: 10.1006/exnr.1994.1209. [DOI] [PubMed] [Google Scholar]

[CR23] 23.Pasinetti GM. Inflammatory mechanisms in neurodegeneration and Alzheimer’s disease: the role of the complement system. Neurobiol Aging. 1996;17:707–716. doi: 10.1016/0197-4580(96)00113-3. [DOI] [PubMed] [Google Scholar]

[CR24] 24.Atwood CS, Martins RN, Smith MA, Perry G. Senile plaque composition and posttranslational modification of amyloid-β pep-tide and associated proteins. Peptides. 2002;23:1343–1350. doi: 10.1016/s0196-9781(02)00070-0. [DOI] [PubMed] [Google Scholar]

[CR25] 25.Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–890. doi: 10.1016/s0006-291x(84)80190-4. [DOI] [PubMed] [Google Scholar]

[CR26] 26.Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer’s disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82:4245–4249. doi: 10.1073/pnas.82.12.4245. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR27] 27.Perlmutter LS, Barron E, Chui HC. Morphologic association between microglia and senile plaque amyloid in Alzheimer’s disease. Neurosci Lett. 1990;119:32–36. doi: 10.1016/0304-3940(90)90748-x. [DOI] [PubMed] [Google Scholar]

[CR28] 28.Dickson DW, Lee SC, Mattiace LA, Yen S-HC, Brosnan CF. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer’s disease. Glia. 1993;7:75–83. doi: 10.1002/glia.440070113. [DOI] [PubMed] [Google Scholar]

[CR29] 29.Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer’s disease. J Neuroimmunol. 1989;24:173–182. doi: 10.1016/0165-5728(89)90115-x. [DOI] [PubMed] [Google Scholar]

[CR30] 30.Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease. Neurobiol Aging. 2003;24:321–331. doi: 10.1016/s0197-4580(02)00090-8. [DOI] [PubMed] [Google Scholar]

[CR31] 31.Ginsberg SD, Crino PB, Lee VM-Y, Eberwine JH, Trojanowski JQ. Sequestration of RNA in Alzheimer’s disease neurofibrillary tangles and senile plaques. Ann Neurol. 1997;41:200–209. doi: 10.1002/ana.410410211. [DOI] [PubMed] [Google Scholar]

[CR32] 32.Iwatsubo T, Saido TC, Mann DMA, Lee VM-Y, Trojanowski JQ. Full-length amyloid-β(1–42(43)) and amino-terminally modified and truncated amyloid β42(43) deposit in diffuse plaques. Am J Pathol. 1996;149:1823–1830. [PMC free article] [PubMed] [Google Scholar]

[CR33] 33.Masliah E, Terry RD, Mallory N, Alford M, Hansen LA. Diffuse plaques do not accentuate synapse loss in Alzheimer’s disease. Am J Pathol. 1990;137:1293–1297. [PMC free article] [PubMed] [Google Scholar]

[CR34] 34.Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999;158:469–490. doi: 10.1006/exnr.1999.7086. [DOI] [PubMed] [Google Scholar]

[CR35] 35.Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology. 2003;60:1495–1500. doi: 10.1212/01.wnl.0000063311.58879.01. [DOI] [PubMed] [Google Scholar]

[CR36] 36.Bussiere T, Friend PD, Sadeghi N, Wicinski B, Lin Gl, Bouras C, et al. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer’s disease. Neuroscience. 2002;112:75–91. doi: 10.1016/s0306-4522(02)00056-8. [DOI] [PubMed] [Google Scholar]

[CR37] 37.Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Aβ causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675–688. doi: 10.1016/j.neuron.2005.01.040. [DOI] [PubMed] [Google Scholar]

[CR38] 38.Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, et al. Intraneuronal Alzheimer A(β)42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869–1879. doi: 10.1016/s0002-9440(10)64463-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR39] 39.Yang AJ, Knauer M, Burdick DA, Glabe C. Intracellular Aβ 1–42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J Biol Chem. 1995;270:14786–14792. doi: 10.1074/jbc.270.24.14786. [DOI] [PubMed] [Google Scholar]

[CR40] 40.Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004;165:1289–1300. doi: 10.1016/s0002-9440(10)63388-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR41] 41.Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998;150:296–304. doi: 10.1006/exnr.1997.6777. [DOI] [PubMed] [Google Scholar]

[CR42] 42.Hirayama A, Horikoshi Y, Maeda M, Ito M, Takashima S. Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome. Brain Dev. 2003;25:180–185. doi: 10.1016/s0387-7604(02)00209-7. [DOI] [PubMed] [Google Scholar]

[CR43] 43.Rovelet-Lecrux A, Hannequin D, Raux G, Meur NL, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer’s disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24–26. doi: 10.1038/ng1718. [DOI] [PubMed] [Google Scholar]

[CR44] 44.Selkoe DJ. Amyloid-β-protein and the genetics of Alzheimer’s disease. J Biol Chem. 1996;271:18295–18298. doi: 10.1074/jbc.271.31.18295. [DOI] [PubMed] [Google Scholar]

[CR45] 45.Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349:704–706. doi: 10.1038/349704a0. [DOI] [PubMed] [Google Scholar]

[CR46] 46.Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Aβ1–42/40 ratioin vitro and in vivo. Neuron. 1996;17:1005–1013. doi: 10.1016/s0896-6273(00)80230-5. [DOI] [PubMed] [Google Scholar]

[CR47] 47.Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373:523–527. doi: 10.1038/373523a0. [DOI] [PubMed] [Google Scholar]

[CR48] 48.Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102. doi: 10.1126/science.274.5284.99. [DOI] [PubMed] [Google Scholar]

[CR49] 49.Finckh U, Kuschel C, Anagnostouli M, Patsouris E, Pantes GV, Gatzonis S, et al. Novel mutations and repeated findings of mutations in familial Alzheimer’s disease. Neurogenetics. 2005;6:85–89. doi: 10.1007/s10048-005-0211-x. [DOI] [PubMed] [Google Scholar]

[CR50] 50.Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature. 1995;376:775–778. doi: 10.1038/376775a0. [DOI] [PubMed] [Google Scholar]

[CR51] 51.Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375:754–760. doi: 10.1038/375754a0. [DOI] [PubMed] [Google Scholar]

[CR52] 52.Kovacs DM, Fausett HJ, Page KJ, Kim T-W, Moir RD, Merriam DE, et al. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996;2:224–229. doi: 10.1038/nm0296-224. [DOI] [PubMed] [Google Scholar]

[CR53] 53.Lah JJ, Heilman CJ, Nash NR, Rees HD, Yi H, Counts SE, et al. Light and electron microscopic localization of presenilin-1 in primate brain. J Neurosci. 1997;17:1971–1980. doi: 10.1523/JNEUROSCI.17-06-01971.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR54] 54.Iwatsubo T. The gamma-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol. 2004;14:379–383. doi: 10.1016/j.conb.2004.05.010. [DOI] [PubMed] [Google Scholar]

[CR55] 55.Pasternak SH, Bagshaw RD, Guiral M, Zhang S, Ackerley CA, Pak BJ, et al. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J Biol Chem. 2003;278:26687–26894. doi: 10.1074/jbc.m304009200. [DOI] [PubMed] [Google Scholar]

[CR56] 56.Duff K, Eckman C, Zehr C, Yu X, Prada C-M, Perez-tur J, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710–713. doi: 10.1038/383710a0. [DOI] [PubMed] [Google Scholar]

[CR57] 57.Citron M, Westaway D, Xia W, Carlson G, Levesque G, Johnson-Wood K, et al. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67–72. doi: 10.1038/nm0197-67. [DOI] [PubMed] [Google Scholar]

[CR58] 58.Iwatsubo T, Okada A, Suzuki N, Mizusawa N, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43) Neuron. 1994;13:45–53. doi: 10.1016/0896-6273(94)90458-8. [DOI] [PubMed] [Google Scholar]

[CR59] 59.Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry. 1993;32:4693–4697. doi: 10.1021/bi00069a001. [DOI] [PubMed] [Google Scholar]

[CR60] 60.Jin L-W, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-{β} precursor protein in neurons with Niemann-Pick Type C defects is associated with endosomal abnormalities. Am J Pathol. 2004;164:975–985. doi: 10.1016/s0002-9440(10)63185-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR61] 61.Hauser ER, Pericak-Vance MA. Genetic analysis for common complex disease. Am Heart J. 2000;140:S36–S44. doi: 10.1067/mhj.2000.108946. [DOI] [PubMed] [Google Scholar]

[CR62] 62.Bently DR, Dunham I. Mapping human chromosomes. Curr Opin Genet Dev. 1995;5:328–334. doi: 10.1016/0959-437x(95)80047-6. [DOI] [PubMed] [Google Scholar]

[CR63] 63.Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, et al. Identification of novel genes in late-onset Alzheimer’s disease. Exp Gerontol. 2000;35:1343–1352. doi: 10.1016/s0531-5565(00)00196-0. [DOI] [PubMed] [Google Scholar]

[CR64] 64.Olson JM, Goddard KA, Dudek DM. A second locus for verylate-onset Alzheimer’s disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum Genet. 2002;71:154–161. doi: 10.1086/341034. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR65] 65.Grupe A, Li Y, Rowland C, Nowotny P, Hinrichs AL, Smemo S, et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer’s disease. Am J Hum Genet. 2006;78:78–88. doi: 10.1086/498851. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR66] 66.Schmitz C, Rutten BPF, Pielen A, Schafer S, Wirths O, Tremp G, et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer’s disease. Am J Pathol. 2004;164:1495–1502. doi: 10.1016/S0002-9440(10)63235-X. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR67] 67.Couchie D, Mavilia C, Georgieff IS, Liem RK, Shelanski ML, Nunez J. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci USA. 1992;89:4378–4381. doi: 10.1073/pnas.89.10.4378. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR68] 68.Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol. 1985;101:1371–1378. doi: 10.1083/jcb.101.4.1371. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR69] 69.Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739:240–250. doi: 10.1016/j.bbadis.2004.08.007. [DOI] [PubMed] [Google Scholar]

[CR70] 70.Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8:393–399. doi: 10.1002/j.1460-2075.1989.tb03390.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR71] 71.Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989;3:519–526. doi: 10.1016/0896-6273(89)90210-9. [DOI] [PubMed] [Google Scholar]

[CR72] 72.Goode BL, Feinstein SC. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol. 1994;124:769–782. doi: 10.1083/jcb.124.5.769. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR73] 73.Ginsberg SD, Che S, Counts SE, Mufson EJ. Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. J Neurochem. 2006;96:1401–1408. doi: 10.1111/j.1471-4159.2005.03641.x. [DOI] [PubMed] [Google Scholar]

[CR74] 74.Drecshel DN, Hyman AA, Cobb MH, Kirschner M. Modulation of the dynamic instability of tubulin assembly by the microtubule associated protein tau. Mol Biol Cell. 1992;3:1147–1154. doi: 10.1091/mbc.3.10.1141. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR75] 75.Kosik KS, Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim Biophys Acta. 2005;1739:298–310. doi: 10.1016/j.bbadis.2004.10.011. [DOI] [PubMed] [Google Scholar]

[CR76] 76.Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem. 1995;270:823–829. doi: 10.1074/jbc.270.2.823. [DOI] [PubMed] [Google Scholar]

[CR77] 77.Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, et al. Tau is a candidate gene for chromosome 17 fronto-temporal dementia. Ann Neurol. 1998;43:815–825. doi: 10.1002/ana.410430617. [DOI] [PubMed] [Google Scholar]

[CR78] 78.Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–705. doi: 10.1038/31508. [DOI] [PubMed] [Google Scholar]

[CR79] 79.Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–1159. doi: 10.1146/annurev.neuro.24.1.1121. [DOI] [PubMed] [Google Scholar]

[CR80] 80.Ingram EM, Spillantini MG. Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol Med. 2002;8:555–562. doi: 10.1016/s1471-4914(02)02440-1. [DOI] [PubMed] [Google Scholar]

[CR81] 81.Mott RT, Dickson DW, Trojanowski JQ, Zhukareva V, Lee VM, Forman M, et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol. 2005;64:420–428. doi: 10.1093/jnen/64.5.420. [DOI] [PubMed] [Google Scholar]

[CR82] 82.Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol. 1998;8:387–402. doi: 10.1111/j.1750-3639.1998.tb00162.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR83] 83.Bergmann M, Kuchelmeister K, Schmid KW, Kretzschmar HA, Schroder R. Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study. Acta Neuropathol (Berl) 1996;92:170–179. doi: 10.1007/s004010050505. [DOI] [PubMed] [Google Scholar]

[CR84] 84.Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282:1914–1917. doi: 10.1126/science.282.5395.1914. [DOI] [PubMed] [Google Scholar]

[CR85] 85.Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde Y-A, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582–590. doi: 10.1046/j.1471-4159.2003.01879.x. [DOI] [PubMed] [Google Scholar]

[CR86] 86.Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446–5454. doi: 10.1523/JNEUROSCI.4637-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR87] 87.Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem. 2001;276:529–534. doi: 10.1074/jbc.M006531200. [DOI] [PubMed] [Google Scholar]

[CR88] 88.Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J Neurosci. 2005;25:10637–10647. doi: 10.1523/JNEUROSCI.3279-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR89] 89.Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, et al. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol. 2005;166:521–531. doi: 10.1016/S0002-9440(10)62274-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR90] 90.Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer’s disease. Neurobiol Aging. 2005;26:355–361. doi: 10.1016/j.neurobiolaging.2004.09.003. [DOI] [PubMed] [Google Scholar]

[CR91] 91.Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA. 1995;92:4725–4727. doi: 10.1073/pnas.92.11.4725. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR92] 92.Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, et al. ApoE-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiative. Neurology. 1997;48:139–147. doi: 10.1212/wnl.48.1.139. [DOI] [PubMed] [Google Scholar]

[CR93] 93.Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, et al. Apolipoprotein E s4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology. 2003;60:246–252. doi: 10.1212/01.wnl.0000042478.08543.f7. [DOI] [PubMed] [Google Scholar]

[CR94] 94.Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–923. doi: 10.1126/science.8346443. [DOI] [PubMed] [Google Scholar]

[CR95] 95.Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer’s disease. Nat Genet. 1994;7:180–184. doi: 10.1038/ng0694-180. [DOI] [PubMed] [Google Scholar]

[CR96] 96.Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–630. doi: 10.1126/science.3283935. [DOI] [PubMed] [Google Scholar]

[CR97] 97.Lahiri DK. Apolipoprotein E as a target for developing new therapeutics for Alzheimer’s disease based on studies from protein, RNA, and regulatory region of the gene. J Mol Neurosci. 2004;23:225–233. doi: 10.1385/JMN:23:3:225. [DOI] [PubMed] [Google Scholar]

[CR98] 98.Benzing WC, Mufson EJ. Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to tau and PHF in Alzheimer’s disease. Exp Neurol. 1995;132:162–171. doi: 10.1016/0014-4886(95)90021-7. [DOI] [PubMed] [Google Scholar]

[CR99] 99.Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-M, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloidβ peptide: isoform-specific effects and implications for late-onset Alzheimer’s disease. Proc Natl Acad Sci USA. 1993;90:8098–8102. doi: 10.1073/pnas.90.17.8098. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR100] 100.Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer’s fibril formation by apolipoprotein Ein vitro. Am J Pathol. 1994;145:1030–1035. [PMC free article] [PubMed] [Google Scholar]

[CR101] 101.Sanan DA, Weisgraber K, Russell SJ, Mahley RW, Huang D, Saunders A, et al. Apolipoprotein E associates with Aβ amyloid peptide to form novel monofibrils: isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994;94:860–869. doi: 10.1172/JCI117407. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR102] 102.Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong L-M, Jakes R, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer’s disease. Proc Natl Acad Sci USA. 1994;91:11183–11186. doi: 10.1073/pnas.91.23.11183. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR103] 103.Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163–166. doi: 10.1016/0006-8993(91)91092-f. [DOI] [PubMed] [Google Scholar]

[CR104] 104.Bao F, Arai H, Matsushita S, Higuchi S, Sasaki H. Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. NeuroReport. 1996;7:1733–1739. doi: 10.1097/00001756-199607290-00008. [DOI] [PubMed] [Google Scholar]

[CR105] 105.Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PN, Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci. 2003;23:5219–5226. doi: 10.1523/JNEUROSCI.23-12-05219.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR106] 106.Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum Mol Genet. 2004;13:1225–1240. doi: 10.1093/hmg/ddh140. [DOI] [PubMed] [Google Scholar]

[CR107] 107.Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA. 2004;101:2173–2178. doi: 10.1073/pnas.0308512100. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR108] 108.Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res. 2002;70:462–473. doi: 10.1002/jnr.10351. [DOI] [PubMed] [Google Scholar]

[CR109] 109.Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer’s disease. DNA Cell Biol. 2001;20:683–695. doi: 10.1089/10445490152717541. [DOI] [PubMed] [Google Scholar]

[CR110] 110.Lukiw WJ. Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem Res. 2004;29:1287–1297. doi: 10.1023/b:nere.0000023615.89699.63. [DOI] [PubMed] [Google Scholar]

[CR111] 111.Minagar A, Shapshak P, Duran EM, Kablingerm AS, Alexander JS, Kelley RE, et al. HIV-associated dementia, Alzheimer’s disease, multiple sclerosis, and schizophrenia: gene expression review. J Neurol Sci. 2004;224:3–17. doi: 10.1016/j.jns.2004.06.007. [DOI] [PubMed] [Google Scholar]

[CR112] 112.Roy Walker P, Smith B, Liu QY, Fazel Famili A, Valdes JJ, Liu Z, et al. Data mining of gene expression changes in Alzheimer brain. Artif Intell Med. 2004;31:137–154. doi: 10.1016/j.artmed.2004.01.008. [DOI] [PubMed] [Google Scholar]

[CR113] 113.Katsel PL, Davis KL, Haroutunian V. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer’s disease. Int Rev Neurobiol. 2005;63:41–82. doi: 10.1016/S0074-7742(05)63003-6. [DOI] [PubMed] [Google Scholar]

[CR114] 114.Marcotte ER, Srivastava LK, Quirion R. cDNA microarray and proteomic approaches in the study of brain diseases: focus on schizophrenia and Alzheimer’s disease. Pharmacol Ther. 2003;100:63–74. doi: 10.1016/s0163-7258(03)00086-x. [DOI] [PubMed] [Google Scholar]

[CR115] 115.Ricciarelli R, d’Abramo C, Massone S, Marinari U, Pronzato M, Tabaton M. Microarray analysis in Alzheimer’s disease and normal aging. IUBMB Life. 2004;56:349–354. doi: 10.1080/15216540412331286002. [DOI] [PubMed] [Google Scholar]

[CR116] 116.Blalock EM, Chen KC, Stromberg AJ, Norris CM, Kadish I, Kraner SD, et al. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer’s disease: statistical reliability and functional correlation. Aging Res Rev. 2005;4:481–512. doi: 10.1016/j.arr.2005.06.006. [DOI] [PubMed] [Google Scholar]

[CR117] 117.Ginsberg SD. RNA amplification strategies for small sample populations. Methods. 2005;37:229–237. doi: 10.1016/j.ymeth.2005.09.003. [DOI] [PubMed] [Google Scholar]

[CR118] 118.Ginsberg SD, Hemby SE, Mufson EJ, Martin LJ. Cell and tissue microdissection in combination with genomic and proteomic applications. In: Zaborszky L, Wouterlood F, Lanciego JL, editors. Neuroanatomical tract tracing 3: Molecules-neurons-systems. New York: Springer/Kluwer/Plenum; 2006. pp. 109–141. [Google Scholar]

[CR119] 119.Counts SE, Chen EY, Che S, Ikonomovic MD, Wuu J, Ginsberg SD, et al. Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2006;21:205–214. doi: 10.1159/000090906. [DOI] [PubMed] [Google Scholar]

[CR120] 120.Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer’s disease. J Neurochem. 2006;97:475–487. doi: 10.1111/j.1471-4159.2006.03764.x. [DOI] [PubMed] [Google Scholar]

[CR121] 121.Fasulo WH, Hemby SE. Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration. J Neurochem. 2003;87:205–219. doi: 10.1046/j.1471-4159.2003.01986.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR122] 122.Tang WX, Fasulo WH, Mash DC, Hemby SE. Molecular profiling of midbrain dopamine regions in cocaine overdose victims. J Neurochem. 2003;85:911–924. doi: 10.1046/j.1471-4159.2003.01740.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR123] 123.Greene JG, Dingledine R, Greenamyre JT. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis. 2005;18:19–31. doi: 10.1016/j.nbd.2004.10.003. [DOI] [PubMed] [Google Scholar]

[CR124] 124.Kamme F, Salunga R, Yu J, Tran DT, Zhu J, Luo L, et al. Single-cell microarray analysis in hippocampus CA1: demonstration and validation of cellular heterogeneity. J Neurosci. 2003;23:3607–3615. doi: 10.1523/JNEUROSCI.23-09-03607.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR125] 125.Luo L, Salunga RC, Guo H, Bittner A, Joy KC, Galindo JE, et al. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med. 1999;5:117–122. doi: 10.1038/4806. [DOI] [PubMed] [Google Scholar]

[CR126] 126.Ginsberg SD, Che S. Combined histochemical staining, RNA amplification, regional, and single cell analysis within the hippocampus. Lab Invest. 2004;84:952–962. doi: 10.1038/labinvest.3700110. [DOI] [PubMed] [Google Scholar]

[CR127] 127.Vincent VA, DeVoss JJ, Ryan HS, Murphy GM. Analysis of neuronal gene expression with laser capture microdissection. J Neurosci Res. 2002;69:578–586. doi: 10.1002/jnr.10329. [DOI] [PubMed] [Google Scholar]

[CR128] 128.Ginsberg SD, Elarova I, Ruben M, Tan F, Counts SE, Eberwine JH, et al. Single cell gene expression analysis: implications for neurodegenerative and neuropsychiatrie disorders. Neurochem Res. 2004;29:1054–1065. doi: 10.1023/b:nere.0000023593.77052.f7. [DOI] [PubMed] [Google Scholar]

[CR129] 129.Ginsberg SD, Che S. Expression profile analysis within the human hippocampus: comparison of CA1 and CA3 pyramidal neurons. J Comp Neurol. 2005;487:107–118. doi: 10.1002/cne.20535. [DOI] [PubMed] [Google Scholar]

[CR130] 130.Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, et al. Laser capture microdissection: molecular analysis of tissue. Science. 1997;278:1481–1483. doi: 10.1126/science.278.5342.1481. [DOI] [PubMed] [Google Scholar]

[CR131] 131.Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science. 1996;274:998–1001. doi: 10.1126/science.274.5289.998. [DOI] [PubMed] [Google Scholar]

[CR132] 132.Ginsberg SD. Glutamatergic neurotransmission expression profiling in the mouse hippocampus after perforant-path transection. Am J Geriatr Psychiatry. 2005;13:1052–1061. doi: 10.1176/appi.ajgp.13.12.1052. [DOI] [PubMed] [Google Scholar]

[CR133] 133.Ginsberg SD, Che S. RNA amplification in brain tissues. Neurochem Res. 2002;27:981–992. doi: 10.1023/a:1020944502581. [DOI] [PubMed] [Google Scholar]

[CR134] 134.Ginsberg SD, Crino PB, Hemby SE, Weingarten JA, Lee VM-Y, Eberwine JH, et al. Predominance of neuronal mRNAs in individual Alzheimer’s disease senile plaques. Ann Neurol. 1999;45:174–181. [PubMed] [Google Scholar]

[CR135] 135.Ginsberg SD, Hemby SE, Lee VM-Y, Eberwine JH, Trojanowski JQ. Expression profile of transcripts in Alzheimer’s disease tangle-bearing CA1 neurons. Ann Neurol. 2000;48:77–87. [PubMed] [Google Scholar]

[CR136] 136.Hemby SE, Ginsberg SD, Brunk B, Arnold SE, Trojanowski JQ, Eberwine JH. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry. 2002;59:631–640. doi: 10.1001/archpsyc.59.7.631. [DOI] [PubMed] [Google Scholar]

[CR137] 137.Hemby SE, Trojanowski JQ, Ginsberg SD. Neuron-specific age-related decreases in dopamine receptor subtype mRNAs. J Comp Neurol. 2003;456:176–183. doi: 10.1002/cne.10525. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR138] 138.Mufson EJ, Counts SE, Ginsberg SD. Single cell gene expression profiles of nucleus basalis cholinergic neurons in Alzheimer’s disease. Neurochem Res. 2002;27:1035–1048. doi: 10.1023/a:1020952704398. [DOI] [PubMed] [Google Scholar]

[CR139] 139.Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, et al. Analysis of gene expression in single live neurons. Proc Natl Acad Sci USA. 1992;89:3010–3014. doi: 10.1073/pnas.89.7.3010. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR140] 140.Eberwine J, Kacharmina JE, Andrews C, Miyashiro K, McIntosh T, Becker K, et al. mRNA expression analysis of tissue sections and single cells. J Neurosci. 2001;21:8310–8314. doi: 10.1523/JNEUROSCI.21-21-08310.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR141] 141.Eberwine J, Belt B, Kacharmina JE, Miyashiro K. Analysis of subcellularly localized mRNAs usingin situ hybridization, mRNA amplification, and expression profiling. Neurochem Res. 2002;27:1065–1077. doi: 10.1023/a:1020956805307. [DOI] [PubMed] [Google Scholar]

[CR142] 142.van Gelder R, von Zastrow M, Yool A, Dement W, Barchas J, Eberwine J. Amplified RNA (aRNA) synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA. 1990;87:1663–1667. doi: 10.1073/pnas.87.5.1663. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR143] 143.Cheetham JE, Coleman PD, Chow N. Isolation of single immunohistochemically identified whole neuronal cell bodies from post-mortem human brain for simultaneous analysis of multiple gene expression. J Neurosci Methods. 1997;77:43–48. doi: 10.1016/s0165-0270(97)00109-x. [DOI] [PubMed] [Google Scholar]

[CR144] 144.Chow N, Cox C, Callahan LM, Weimer JM, Guo L, Coleman PD. Expression profiles of multiple genes in single neurons of Alzheimer’s disease. Proc Natl Acad Sci USA. 1998;95:9620–9625. doi: 10.1073/pnas.95.16.9620. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR145] 145.Mufson EJ, Counts SE, Che S, Ginsberg SD. Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease.Prog Neurobiol (in press). [DOI] [PubMed]

[CR146] 146.Ginsberg SD, Mimics K. Functional genomics methodologies.Prog Neurobiol (in press).

[CR147] 147.Dafforn A, Chen P, Deng G, Herrler M, Iglehart D, Koritala S, et al. Linear mRNA amplification from as little as 5 ng total RNA for global gene expression analysis. BioTechniques. 2004;37:854–857. doi: 10.2144/04375PF01. [DOI] [PubMed] [Google Scholar]

[CR148] 148.Kurn N, Chen P, Heath JD, Kopf-Sill A, Stephens KM, Wang S. Novel isothermal, linear nucleic acid amplification systems for highly multiplexed applications. Clin Chem. 2005;51:1973–1981. doi: 10.1373/clinchem.2005.053694. [DOI] [PubMed] [Google Scholar]

[CR149] 149.Che S, Ginsberg SD. Amplification of transcripts using terminal continuation. Lab Invest. 2004;84:131–137. doi: 10.1038/labinvest.3700005. [DOI] [PubMed] [Google Scholar]

[CR150] 150.Che S, Ginsberg SD. RNA amplification methodologies. In: Trends in RNA research. Hauppauge, NY: Nova Science Publishing (in press).

[CR151] 151.Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999;21:33–37. doi: 10.1038/4462. [DOI] [PubMed] [Google Scholar]

[CR152] 152.Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol. 1999;303:179–205. doi: 10.1016/s0076-6879(99)03014-1. [DOI] [PubMed] [Google Scholar]

[CR153] 153.Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467–470. doi: 10.1126/science.270.5235.467. [DOI] [PubMed] [Google Scholar]

[CR154] 154.Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high density oligonucleotide arrays. Nat Biotechnol. 1996;14:1675–1680. doi: 10.1038/nbt1296-1675. [DOI] [PubMed] [Google Scholar]

[CR155] 155.Olson NE. The microarray data analysis process: from raw data to biological significance. NeuroRx. 2006;3:371–381. doi: 10.1016/j.nurx.2006.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR156] 156.Almudevar A, Klebanov LB, Qiu X, Salzman P, Yakovlev AY. Utility of correlation measures in analysis of gene expression. NeuroRx. 2006;3:382–393. doi: 10.1016/j.nurx.2006.05.037. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR157] 157.Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999;19:1720–1730. doi: 10.1128/mcb.19.3.1720. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR158] 158.Ginsberg SD, Galvin JE, Chiu T-S, Lee VM-Y, Masliah E, Trojanowski JQ. RNA sequestration to pathological lesions of neurodegenerative disorders. Acta Neuropathol. 1998;96:487–494. doi: 10.1007/s004010050923. [DOI] [PubMed] [Google Scholar]

[CR159] 159.Topaloglu H, Samat HB. Acridine orange-RNA fluorescence maturing neurons in the perinatal rat brain. Anat Rec. 1989;224:88–93. doi: 10.1002/ar.1092240111. [DOI] [PubMed] [Google Scholar]

[CR160] 160.Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 1997;77:1037–1048. doi: 10.1016/s0306-4522(96)00545-3. [DOI] [PubMed] [Google Scholar]

[CR161] 161.Eikelenboom P, Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer’s disease. Neurobiol Aging. 1996;17:673–680. doi: 10.1016/0197-4580(96)00108-x. [DOI] [PubMed] [Google Scholar]

[CR162] 162.Sarnat HB, Curry B, Rewcastle NB, Trevenen CL. Gliosis and glioma distinguished by acridine orange. Can J Neurol Sci. 1987;14:31–35. doi: 10.1017/s0317167100026135. [DOI] [PubMed] [Google Scholar]

[CR163] 163.Burbach GJ, Dehn D, Nagel B, Del Turco D, Deller T. Laser microdissection of immunolabeled astrocytes allows quantification of astrocytic gene expression. J Neurosci Methods. 2004;138:141–148. doi: 10.1016/j.jneumeth.2004.03.022. [DOI] [PubMed] [Google Scholar]

[CR164] 164.Burbach GJ, Dehn D, Del Turco D, Staufenbiel M, Deller T. Laser microdissection reveals regional and cellular differences in GFAP mRNA upregulation following brain injury, axonal denervation, and amyloid plaque deposition. Glia. 2004;48:76–84. doi: 10.1002/glia.20057. [DOI] [PubMed] [Google Scholar]

[CR165] 165.Harrison PJ, Barton AJ, Najlerahim A, McDonald B, Pearson RC. Regional and neuronal reductions of polyadenylated messenger RNA in Alzheimer’s disease. Psychol Med. 1991;21:855–866. doi: 10.1017/s0033291700029858. [DOI] [PubMed] [Google Scholar]

[CR166] 166.Griffin WS, Ling C, White CL, Morrison-Bogorad M. Polyadenylated messenger RNA in paired helical filament-immunoreactive neurons in Alzheimer’s disease. Alzheimer Dis Assoc Dis. 1990;4:69–78. [PMC free article] [PubMed] [Google Scholar]

[CR167] 167.Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci. 2005;22:1942–1950. doi: 10.1111/j.1460-9568.2005.04391.x. [DOI] [PubMed] [Google Scholar]

[CR168] 168.Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp Neurol. 2001;168:402–412. doi: 10.1006/exnr.2001.7630. [DOI] [PubMed] [Google Scholar]

[CR169] 169.Goedert M, Jakes R, Qi Z, Wang JH, Cohen P. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates t protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J Neurochem. 1995;65:2804–2807. doi: 10.1046/j.1471-4159.1995.65062804.x. [DOI] [PubMed] [Google Scholar]

[CR170] 170.Joyce JN, Kaeger C, Ryoo H, Goldsmith S. Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer’s disease. Neurosci Lett. 1993;154:171–174. doi: 10.1016/0304-3940(93)90199-u. [DOI] [PubMed] [Google Scholar]

[CR171] 171.Ryoo HL, Joyce JN. Loss of dopamine D2 receptors varies along the rostrocaudal axis of the hippocampal complex in Alzheimer’s disease. J Comp Neurol. 1994;348:94–110. doi: 10.1002/cne.903480105. [DOI] [PubMed] [Google Scholar]

[CR172] 172.Rinne JO, Lonnberg P, Marjamaki P. Age-dependent decline in human brain dopamine D1 and D2 receptors. Brain Res. 1990;508:349–352. doi: 10.1016/0006-8993(90)90423-9. [DOI] [PubMed] [Google Scholar]

[CR173] 173.Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol. 1998;44:143–147. doi: 10.1002/ana.410440125. [DOI] [PubMed] [Google Scholar]

[CR174] 174.Amenta F, Mignini F, Ricci A, Sabbatini M, Tomassoni D, Tayebati SK. Age-related changes of dopamine receptors in the rat hippocampus: a light microscope autoradiography study. Mech Aging Dev. 2001;122:2071–2083. doi: 10.1016/s0047-6374(01)00317-7. [DOI] [PubMed] [Google Scholar]

[CR175] 175.Gutala RV, Reddy PH. The use of real-time PCR analysis in a gene expression study of Alzheimer’s disease post-mortem brains. J Neurosci Methods. 2004;132:101–107. doi: 10.1016/j.jneumeth.2003.09.005. [DOI] [PubMed] [Google Scholar]

[CR176] 176.Callahan LM, Vaules WA, Coleman PD. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer’s disease neurons containing neurofibrillary tangles. J Neuropathol Exp Neurol. 1999;58:275–287. doi: 10.1097/00005072-199903000-00007. [DOI] [PubMed] [Google Scholar]

[CR177] 177.Heffeman JM, Eastwood SL, Nagy Z, Sanders MW, McDonald B, Harrison PJ. Temporal cortex synaptophysin mRNA is reduced in Alzheimer’s disease and is negatively correlated with the severity of dementia. Exp Neurol. 1998;150:235–239. doi: 10.1006/exnr.1997.6772. [DOI] [PubMed] [Google Scholar]

[CR178] 178.Shimohama S, Kamiya S, Taniguchi T, Akagawa K, Kimura J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer’s disease. Biochem Biophys Res Commun. 1997;236:239–242. doi: 10.1006/bbrc.1997.6940. [DOI] [PubMed] [Google Scholar]

[CR179] 179.Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer’s disease. J Neuropathol Exp Neurol. 1997;56:933–944. doi: 10.1097/00005072-199708000-00011. [DOI] [PubMed] [Google Scholar]

[CR180] 180.Sze CI, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer’s disease brains. J Neurol Sci. 2000;175:81–90. doi: 10.1016/s0022-510x(00)00285-9. [DOI] [PubMed] [Google Scholar]

[CR181] 181.Cataldo AM, Paskevich PA, Kominami E, Nixon RA. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer’s disease. Proc Nail Acad Sci USA. 1991;88:10998–11002. doi: 10.1073/pnas.88.24.10998. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR182] 182.Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, et al. Gene expression and cellular content of cathepsin D in Alzheimer’s disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron. 1995;14:671–680. doi: 10.1016/0896-6273(95)90324-0. [DOI] [PubMed] [Google Scholar]

[CR183] 183.Cataldo AM, Bamett JL, Picroni C, Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer’s disease: neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J Neurosci. 1997;17:6142–6151. doi: 10.1523/JNEUROSCI.17-16-06142.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR184] 184.Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, et al. Macroautophagy: a novel β-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol. 2005;171:87–98. doi: 10.1083/jcb.200505082. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR185] 185.Nixon RA. Endosome function and dysfunction in Alzheimer’s disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373–382. doi: 10.1016/j.neurobiolaging.2004.09.018. [DOI] [PubMed] [Google Scholar]

[CR186] 186.Cataldo AM, Hamilton DJ, Bamett JL, Paskevich PA, Nixon RA. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer’s disease. J Neurosci. 1996;16:186–199. doi: 10.1523/JNEUROSCI.16-01-00186.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR187] 187.Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol. 1983;214:170–197. doi: 10.1002/cne.902140206. [DOI] [PubMed] [Google Scholar]

[CR188] 188.Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–414. doi: 10.1126/science.7046051. [DOI] [PubMed] [Google Scholar]

[CR189] 189.Baxter MG, Chiba AA. Cognitive functions of the basal fore-brain. Curr Opin Neurobiol. 1999;9:178–183. doi: 10.1016/s0959-4388(99)80024-5. [DOI] [PubMed] [Google Scholar]

[CR190] 190.Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2:1403–1403. doi: 10.1016/s0140-6736(76)91936-x. [DOI] [PubMed] [Google Scholar]

[CR191] 191.Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, et al. Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits. J Neurochem. 1995;64:749–760. doi: 10.1046/j.1471-4159.1995.64020749.x. [DOI] [PubMed] [Google Scholar]

[CR192] 192.Auld DS, Komecook TJ, Bastianetto S, Quirion R. Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68:209–245. doi: 10.1016/s0301-0082(02)00079-5. [DOI] [PubMed] [Google Scholar]

[CR193] 193.Galvin JE, Ginsberg SD. Expression profiling in the aging brain: a perspective. Aging Res Rev. 2005;4:529–547. doi: 10.1016/j.arr.2005.06.009. [DOI] [PubMed] [Google Scholar]

[CR194] 194.Galvin JE, Ginsberg SD. Expression profiling and pharmacotherapeutic development in the central nervous system. Alzheimer Dis Assoc Disord. 2004;18:264–269. [PubMed] [Google Scholar]

[CR195] 195.Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol. 2004;55:815–828. doi: 10.1002/ana.20100. [DOI] [PubMed] [Google Scholar]

[CR196] 196.Counts SE, Mufson EJ. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer’s disease. J Neuropathol Exp Neurol. 2005;64:263–272. doi: 10.1093/jnen/64.4.263. [DOI] [PubMed] [Google Scholar]

[CR197] 197.Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer’s disease. J Comp Neurol. 2000;427:19–30. doi: 10.1002/1096-9861(20001106)427:1<19::aid-cne2>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]

[CR198] 198.Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198–205. doi: 10.1212/wnl.59.2.198. [DOI] [PubMed] [Google Scholar]

[CR199] 199.King ME, Gamblin TC, Kuret J, Binder LI. Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem. 2000;74:1749–1757. doi: 10.1046/j.1471-4159.2000.0741749.x. [DOI] [PubMed] [Google Scholar]

[CR200] 200.Levy SF, Leboeuf AC, Massie MR, Jordan MA, Wilson L, Feinstein SC. Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners: implications for neurodegeneration. J Biol Chem. 2005;280:13520–13528. doi: 10.1074/jbc.M413490200. [DOI] [PubMed] [Google Scholar]

[CR201] 201.Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA. Over-expression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer’s disease. Ann Neurol. 1999;46:325–332. doi: 10.1002/1531-8249(199909)46:3<325::aid-ana8>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]

[CR202] 202.de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol. 2003;29:288–302. doi: 10.1046/j.1365-2990.2003.00463.x. [DOI] [PubMed] [Google Scholar]

[CR203] 203.Arai T, Ikeda K, Akiyama H, Tsuchiya K, Iritani S, Ishiguro K, et al. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berl) 2003;105:489–498. doi: 10.1007/s00401-003-0671-8. [DOI] [PubMed] [Google Scholar]

[CR204] 204.Fujino Y, Wang DS, Thomas N, Espinoza M, Davies P, Dickson DW. Increased frequency of argyrophilic grain disease in Alzheimer disease with 4R tau-specific immunohistochemistry. J Neuropathol Exp Neurol. 2005;64:209–214. doi: 10.1093/jnen/64.3.209. [DOI] [PubMed] [Google Scholar]

[CR205] 205.Zhukareva V, Shah K, Uryu K, Braak H, Del Tredici K, Sundarraj S, et al. Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer’s disease, and Pick’s disease: a comparative study. Am J Pathol. 2002;161:1135–1141. doi: 10.1016/s0002-9440(10)64390-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR206] 206.Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat. 2003;26:233–242. doi: 10.1016/s0891-0618(03)00068-1. [DOI] [PubMed] [Google Scholar]

[CR207] 207.Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217–1281. doi: 10.1146/annurev.neuro.24.1.1217. [DOI] [PubMed] [Google Scholar]

[CR208] 208.Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer’s disease. Ann Neurol. 2004;56:520–531. doi: 10.1002/ana.20233. [DOI] [PubMed] [Google Scholar]

[CR209] 209.Colantuoni C, Purcell AE, Bouton CM, Pevsner J. High throughput analysis of gene expression in the human brain. J Neurosci Res. 2000;59:1–10. doi: 10.1002/(sici)1097-4547(20000101)59:1<1::aid-jnr1>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]

[CR210] 210.Serafini T. Of neurons and gene chips. Curr Opin Neurobiol. 1999;9:641–644. doi: 10.1016/s0959-4388(99)00022-7. [DOI] [PubMed] [Google Scholar]

PERMALINK

Single cell gene expression profiling in Alzheimer’s disease

Stephen D Ginsberg

Shaoli Che

Scott E Counts

Elliott J Mufson

Summary

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Single cell gene expression profiling in Alzheimer’s disease

Stephen D Ginsberg

Shaoli Che

Scott E Counts

Elliott J Mufson

Summary

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases